National Bank of Canada’s Accelerate Diagnostics AXDX Stock Holding History

National Bank of Canada’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-160	Closed	-$112	–	2998
2025 Q1	$112	Hold	160	–	–	﹤0.01%	2715
2024 Q4	$192	Hold	160	–	–	﹤0.01%	2764
2024 Q3	$274	Hold	160	–	–	﹤0.01%	2511
2024 Q2	$183	Hold	160	–	–	﹤0.01%	2609
2024 Q1	$141	Buy	+160	New	+$253	﹤0.01%	2653

Other funds holding AXDX

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

BCWM

Bartlett & Co Wealth Management Cincinnati, Ohio $7.99B AUM 20.76% 1-Year Est. Return

National Bank of Canada's AXDX Position: Q2 2025 in Review

National Bank of Canada sold out of Accelerate Diagnostics (AXDX) in Q2 2025, closing a stake of 160 shares — an estimated $112 sold.

National Bank of Canada first reported a position in AXDX in Q1 2024 and held it in 5 quarters. The position peaked at $274 in Q3 2024. 3 funds tracked by Wall St. Rank hold AXDX as of Q2 2025.

National Bank of Canada reported no remaining Accelerate Diagnostics position as of Q2 2025 after selling out during the quarter.
National Bank of Canada sold 160 Accelerate Diagnostics shares in Q2 2025, an estimated $112.
National Bank of Canada first reported a position in Accelerate Diagnostics in Q1 2024 and held it in 5 quarters.
National Bank of Canada's Accelerate Diagnostics position peaked at $274 in Q3 2024.
3 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2025.

Based on National Bank of Canada's 13F filing for Q2 2025, filed 13 Aug 2025.